about
Hepatic glycogenosis: An underdiagnosed complication of diabetes mellitus?Islet cell and thyroid antibody prevalence in patients with hepatitis C virus infection: effect of treatment with interferon.Insulin use and Excess Fracture Risk in Patients with Type 2 Diabetes: A Propensity-Matched cohort analysis.New splice site acceptor mutation in AIRE gene in autoimmune polyendocrine syndrome type 1.Control of postprandial state abnormalities: meeting the challenge of type 2 diabetes?Benign and malignant nodular thyroid disease in acromegaly. Is a routine thyroid ultrasound evaluation advisable?Efferocytosis promotes suppressive effects on dendritic cells through prostaglandin E2 production in the context of autoimmunity.Insulin secretion in patients with latent autoimmune diabetes (LADA): half way between type 1 and type 2 diabetes: action LADA 9Use of autoantigen-loaded phosphatidylserine-liposomes to arrest autoimmunity in type 1 diabetesBreaking Therapeutic Inertia in Type 2 Diabetes: Active Detection of In-Patient Cases Allows Improvement of Metabolic Control at Midterm.Ghrelin Gene Variants Influence on Metabolic Syndrome Components in Aged Spanish Population.Type 1 Diabetes Prevention in NOD Mice by Targeting DPPIV/CD26 Is Associated with Changes in CD8⁺T Effector Memory Subset.Evaluation of efficacy, safety, pain perception and health-related quality of life of percutaneous ethanol injection as first-line treatment in symptomatic thyroid cysts.Hormonal determinants and effect of ER22/23EK glucocorticoid receptor gene polymorphism on health status deterioration in the participants of the Mataró Ageing StudyRelationship of YKL-40 and adiponectin and subclinical atherosclerosis in asymptomatic patients with type 1 diabetes mellitus from a European Mediterranean population.Endocrine evaluation of patients after brain injury: what else is needed to define specific clinical recommendations?Clinical dilemmas arising from the increased intake of iodine in the Spanish population and the recommendation for systematic prescription of potassium iodide in pregnant and lactating women (Consensus of the TDY Working Group of SEEN).The truncated isoform of somatostatin receptor5 (sst5TMD4) is associated with poorly differentiated thyroid cancer.Thyroid hormone upregulates zinc-α2-glycoprotein production in the liver but not in adipose tissue.Recommendations for the pharmacologic treatment of hyperglycemia in type 2 diabetes. Consensus document.Normocalcemic primary hyperparathyroidism: a newly emerging disease needing therapeutic intervention.Adrenal insufficiency and adrenal replacement therapy. Current status in Spain.Controversies in endocrinology: On the need for universal thyroid screening in pregnant women.Glucagon-like peptide-1 receptor agonists as insulin add-on therapy in patients with inadequate glycemic control in type 2 diabetes mellitus: lixisenatide as a new therapeutic option.Transmission of high-risk HLA-DQB1 alleles in Chilean type 1 diabetic patients and their parents: stratification by the presence of ICA or GAD65 autoantibodies.Treatment of acromegaly in the era of personalized and predictive medicine.Endocrinology, diabetes and nutrition: The future is here.The Molecular Registry of Pituitary Adenomas (REMAH): A bet of Spanish Endocrinology for the future of individualized medicine and translational research.Evaluation of Vitamin and Trace Element Requirements after Sleeve Gastrectomy at Long Term.Variability in adherence to rhGH treatment: Socioeconomic causes and effect on children's growth.Long-term treatment with pegvisomant for acromegaly: a 10-year experience.APLP2, RRM2, and PRC1: New Putative Markers for the Differential Diagnosis of Thyroid Follicular Lesions.Role of melatonin in health and disease.Thirty years of human pineal research: do we know its clinical relevance?Islet cell autoimmunity in women with gestational diabetes and risk of progression to insulin-dependent diabetes mellitus.Incretin hormones as immunomodulators of atherosclerosis.Outcome and long-term effects of pregnancy in women with hyperprolactinaemia.Do thyroid cancer patients with basal undetectable Tg measured by current immunoassays require rhTSH testing?Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-[Clinical endocrinologists' perception of the deleterious effects of TSH suppressive therapy in patients with differentiated thyroid carcinoma].
P50
Q28081624-9CE854A4-EA0D-4BA7-AE09-691F683664E2Q31812559-78EDD108-E1D2-48C0-B98A-663546BE70E9Q33812674-BC887629-CFCB-41C1-9676-12ACD86EE08CQ33837243-44340A63-FC2B-417A-AD1E-4389B2784C31Q34024110-9CC65378-B60E-42F5-B12C-A2AC1B711295Q34050636-96BDADCF-CC7D-40A4-B10B-28AB432E0876Q34730167-2D00CCEA-DE37-41B6-97C6-800F6E091339Q34979018-8DB1734E-ED86-432B-B3C2-727D6287928EQ35651667-3C6122C1-378C-401C-B485-665CEB08746BQ35673027-E1E4AC35-EBDF-4824-85D2-B0DFF5C5B47DQ35777130-240EBA4C-FC46-49BF-A2B1-6FD550269C5CQ35837580-9CB9B5BC-4BF5-4F57-80C5-DA2BB18B667CQ35853730-DE13D7B5-5FC2-48BA-BE60-D2A080481C1EQ35916506-1770F7A4-F3D6-467E-972F-F06104A0F913Q36071889-962A6D48-4408-4486-96D9-4EA7CFB821AEQ36912519-A3CE2025-5F1D-4F1D-ABD5-9BCCD45B5788Q37468192-2B4527CC-95DA-4584-9D67-2AA5E492B6A6Q37499468-C92F8116-7738-4485-8559-77BC68CCA88EQ37499691-731E34D9-F6E3-4E0B-87CF-1CE50A2FB64DQ37832659-22822BAD-9153-49EC-9EBB-6B4CE89A435DQ38082963-1D5C8C22-BA91-465D-B5FE-C7AF39C53275Q38086712-9ED0C600-204D-4482-918D-4E31F91CDB2FQ38152841-D8575F17-45DF-42F5-B7A7-2220EF5B0988Q38234424-7A924828-245A-4DFD-8EAC-8A47AB21AD3FQ38295307-A1FACD96-8034-4CFD-8857-D60BEE4259DEQ38340014-328F6E10-F45D-4CBC-A657-2671EA92D59BQ38793123-50E9B22F-958C-4242-8E8C-C780F72D9BDFQ38879404-AFDDDEBC-0FC5-4532-AC5D-83FA81512CB9Q38978583-CD564116-D46F-45B3-85E4-1F07C0C246B9Q40100587-7A82B085-B7A5-476D-8F42-0483ABB08CD5Q40216531-F99DDCE5-BF7D-4F45-A902-EFA728FCE640Q40504305-438DC6D2-66E8-45DA-8030-9BA97A90AE82Q40530244-51F259A3-A037-4AAF-8A39-53A238A63A31Q40997376-6DDCD417-0C3C-4C6D-85C7-D6C8E409DB0DQ41333753-2B19797D-A17A-424F-A673-D56ABB8FFB30Q41882168-9712C959-0519-48B7-8A3B-1A3EBD026AA4Q42457090-9E22946B-7FC9-4254-ABBF-21E70BFD7DF9Q42482975-B6534EE0-1A42-4360-AB8B-C7CD00140029Q42703474-85273E94-2C38-4D89-AA2B-229583FD1594Q43056396-8F870AF7-2E8A-4E3A-A0A1-DFE2C991CFCC
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Manuel Puig-Domingo
@en
Puig-Domingo M
@ast
Puig-Domingo M
@es
Puig-Domingo M
@nl
Puig-Domingo M
@sl
type
label
Manuel Puig-Domingo
@en
Puig-Domingo M
@ast
Puig-Domingo M
@es
Puig-Domingo M
@nl
Puig-Domingo M
@sl
prefLabel
Manuel Puig-Domingo
@en
Puig-Domingo M
@ast
Puig-Domingo M
@es
Puig-Domingo M
@nl
Puig-Domingo M
@sl
P106
P31
P496
0000-0002-6744-7195